Hence, the existence of “FGF21 resistance” during obesity has remained controversial with the prevailing question: how can “FGF21 resistance” exist if pharmacological dosing is still efficacious1? The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.